-
Complement Protein C5 Inhibitor
Vensobafusp alfa is a fusion protein that targets complement protein C5, functioning as a potent inhibitor. It combines an IgG4 monoclonal antibody directed against C5 with the complement factor H 1-5 domain, demonstrating significant anti-inflammatory and immunomodulatory properties. This reagent is applicable in the study of complement-mediated pathologies and therapeutic strategies targeting inflammatory conditions. -
Anticomplement Agent
3-O-(2'E,4'Z-Decadienoyl)ingenol is a natural diterpene that functions as an anticomplement agent, demonstrating significant inhibitory activity with an IC50 of 89.5 μM. This compound is primarily utilized in research applications focused on complement system modulation and potential therapeutic interventions related to autoimmune conditions and inflammation. Its unique mechanism of action offers valuable insights into complement-related pathways in various biological contexts. -
Complement component 3 (C3) synthesis reducer
Cevolisiran is a small interfering RNA (siRNA) that specifically targets and reduces the synthesis of complement component 3 (C3). This reduction in C3 levels may modulate the complement pathway, which is pivotal in immune responses and inflammation. Cevolisiran is primarily used in research applications aimed at understanding the role of the complement system in various diseases and therapeutic strategies. -
Complement System Inhibitor
Bisphenol A bissulfate disodium is a complement system inhibitor with a significant role in modulating immune responses. This compound exhibits complement-inhibiting activity, demonstrating an IC50 value of 247 μM. It is utilized in research applications aimed at understanding the complement pathway and its implications in various diseases, making it a valuable tool in immunological studies. -
Complement inhibitor
Bisphenol S disulfate disodium is a complement inhibitor that exhibits a half-maximal inhibitory concentration (IC50) of 660 μM. This compound is utilized in research applications aiming to explore complement-mediated pathways and their roles in various biological processes and diseases. Its ability to modulate complement activity makes it a valuable tool for studies involving immune response and inflammation. -
Anti-Complement C5 Antibody
Ascuprubart is a monoclonal antibody specifically designed to target human Complement C5. By inhibiting the activity of C5, this antibody plays a crucial role in modulating the complement pathway, making it instrumental in research related to immune response and inflammation. Ascuprubart is suitable for applications in studies focused on complement-mediated diseases and therapeutic development.


